Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Seagen Inc.

< Previous 1 2 3 Next >
News headline image
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
From Seagen Inc.
Via Business Wire
Tickers SGEN SNY
News headline image
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
From Seagen Inc.
Via Business Wire
Tickers GMAB SGEN
News headline image
Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen Appoints Lee Heeson as Executive Vice President, Commercial International
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2021 Financial Results on February 9, 2022
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen to Present at the J.P. Morgan Healthcare Conference
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Patients with HER2-Positive Breast Cancer with Brain Metastases
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual Meeting
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen Reports Third Quarter 2021 Financial Results
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
From Seagen Inc.
Via Business Wire
Tickers GMAB SGEN
News headline image
Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
From Seagen Inc.
Via Business Wire
Tickers SGEN
News headline image
Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021
From Seagen Inc.
Via Business Wire
Tickers SGEN
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.